Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia

Recruiting Phase 2 Interventional Study
Neonatal Encephalopathy
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
0 Minutes – 48 Hours
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
60 (estimated)
Sponsor
Pia Wintermark · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Around the time of birth, some babies experience a condition called asphyxia, which means that their brain and other organs do not receive enough blood and/or oxygen to work properly. This life-threatening condition accounts for nearly 1 out of 4 deaths of all babies around the world, and often leads to severe brain damage, cerebral palsy, epilepsy, and trouble with learning and functioning in eve…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Male and female neonates meeting the criteria for induced hypothermia: * Gestational age ≥36weeks and birth weight ≥1800g; * Evidence of fetal distress, i.e., history of an acute perinatal event, cord pH ≤7.0 or base deficit * 16 mEq/L; * Evidence of neonatal distress, such…
Contacts

Pia Wintermark, MD

+1-514-412-4452

pia.wintermark@mcgill.ca

CONTACT

Gabriel Altit, MD

+1-514-412-4452

gabriel.altit@mcgill.ca

CONTACT